Bis-styrylverbindungen
    46.
    发明公开
    Bis-styrylverbindungen 失效
    二styrylverbindungen。

    公开(公告)号:EP0302441A2

    公开(公告)日:1989-02-08

    申请号:EP88112508.2

    申请日:1988-08-02

    CPC分类号: C08K5/43 C07C317/00 C08K5/41

    摘要: Bis-styrylverbindungen der Formel
    in der

    R¹      gegebenenfalls substituiertes Phenoxysulfonyl, gegebenenfalls substituiertes C₁-C₁₃-Alkylsulfonyl, C₁-C₈-Mono- oder Dialkyl­sulfamoyl, wobei die Alkylkette jeweils durch ein oder mehrere Sauerstoffatome unterbrochen sein kann, oder gegebenenfalls substituiertes Phenylsulfonyl,
    R²      und R³ unabhängig voneinander Wasserstoff, Fluor, Chlor, C₁-C₄-Alkyl, C₁-C₄-Alkoxy oder gegebenenfalls substituiertes Phenoxy,
    R⁴      Fluor, Chlor, Cyano, gegebenenfalls substituiertes Carbamoyl, C₁-C₈-­Alkoxycarbonyl, dessen Alkylkette durch ein oder mehrere Sauerstoff­atome unterbrochen sein kann oder gegebenenfalls substituiertes Phenoxycarbonyl und
    m,      n, p und q gleich oder verschieden sind und jeweils unabhängig voneinander 1 oder 2 bedeuten,

    sowie ihre Verwendung als optische Aufheller für Polyester.

    摘要翻译: 式“IMAGE”的双苯乙烯基化合物,其中R 1表示取代或未取代的苯氧基磺酰基,取代或未取代的C 1 -C 13 - 烷基磺酰基,C 1 -C 8 - 单 - 或二烷基氨磺酰基,可以使烷基链在每个 一个或多个氧原子的情况,或表示取代或未取代的苯基磺酰基,R 2和R 3彼此独立地表示氢,氟,氯,C 1 -C 4 - 烷基,C 1 -C 4 - 烷氧基或取代的 或未取代的苯氧基,R 4表示氟,氯,氰基,取代或未取代的氨基甲酰基,C 1 -C 8 - 烷氧基羰基,其烷基链可被一个或多个氧原子间隔,或取代或未取代的苯氧基羰基,m,n ,p和q相同或不同,并且彼此独立地表示1或2,被用作聚酯的荧光增白剂。

    Spiro-subsituted glutaramide diuretic agents
    47.
    发明公开
    Spiro-subsituted glutaramide diuretic agents 失效
    螺旋替代物戊二酰胺

    公开(公告)号:EP0274234A2

    公开(公告)日:1988-07-13

    申请号:EP87310784.1

    申请日:1987-12-08

    申请人: Pfizer Limited

    摘要: Compounds of the formula
    wherein A completes a 4 or 7 membered carbocyclic ring which may be saturated or mono-unsaturated and which may optionally be fused to a further saturated or unsaturated 5 or 6 membered carbocyclic ring; B is (CH 2 ) m wherein m is an integer of from 1 to 3; each of R and R 4 is independently H, C 1 -C 6 alkyl, benzyl or an alternative biolabile ester-forming group; R 1 is H or C 1 -C 4 alkyl; R 2 and R 3 are each independently H, OH, C 1 -C 4 alkyl or C 1 -C 4 alkoxy; and R 5 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl(C 2 -C 6 alkynyl), C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, C 1 -C 6 alkoxy, -NR 6 R 7 , -NR 8 COR 9 , -NR 8 SO 2 R 9 or a saturated heterocyclic group; or C 1 -C 6 alkyl substituted by one or more substituents chosen from halo, hydroxy, C 1 -C 6 alkoxy, C 2 -C 6 hydroxyalkoxy, C 1 -C 6 alkoxy(C 1 -C 6 alkoxy), C 3 -C 7 cycloalkyl, C 3 -C 7 cycloalkenyl, aryl, aryloxy, arlyoxy(C I -C 4 alkoxy), heterocyclyl, heterocyclyloxy, -NR 6 R 7 , -NR8COR9, -NR 8 SO 2 R 9 , -CONR 6 R 7 , -SH, -S(O) p R 10 , -COR 11 or -CO 2 R 12 ; wherein R 6 and R 7 are each independently H, C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl (optionally substituted by hydroxy or C 1 -C 4 alkoxy), aryl, aryl(C 1 -C 4 alkyl), CrCs alkoxyalkyl, or heterocyclyl; or the two groups R 6 and R 7 are taken together with the nitrogen to which they are attached to form a pyrrolidinyl, piperidino, morpholino, piperazinyl or N-(C 1 -C 4 alkyl)-piperazinyl group; R 8 is H or C 1 -C 4 alkyl; R 9 is C 1 -C 4 alkyl, CF 3 , aryl, aryl(C I -C 4 alkyl), aryl(C 1 -C 4 alkoxy), heterocycyl, C 1 -C 4 alkoxy or NR 6 R 7 wherein R 6 and R 7 are as previously defined; R 10 is C 1 -C 4 alkyl, aryl, heterocyclyl or NR 6 R 7 wherein R 6 and R 7 are as previously defined; R 11 is C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl, aryl or heterocyclyl; R 12 is H or Ci-C 4 alkyl; and p is 0, 1 or 2; or a pharmaceutically acceptable salts thereof or bioprecursor therefor are diuretic agents having utility in the treatment of hypertension, heart failure, renal insufficiency and in other disorders.

    摘要翻译: 其中A完成4或7元碳环,其可以是饱和或单不饱和的,并且可以任选地与另外的饱和或不饱和的5或6元碳环稠合; B是(CH 2)m,其中m是1至3的整数; R和R 4中的每一个独立地是H,C 1 -C 6烷基,苄基或替代的生物不稳定酯形成基团; R 1是H或C 1 -C 4烷基; R 2和R 3各自独立地为H,OH,C 1 -C 4烷基或C 1 -C 4烷氧基; 并且R 5是C 1 -C 6烷基,C 2 -C 6烯基,C 2 -C 6炔基,芳基(C 2 -C 6炔基),C 3 -C 7环烷基,C 3 -C 7环烯基,C 1 -C 6烷氧基,-NR 6 R -NR 8 COR 9,-NR 8 SO 2 R 9或饱和杂环基; 或被一个或多个选自卤素,羟基,C 1 -C 6烷氧基,C 2 -C 6羟基烷氧基,C 1 -C 6烷氧基(C 1 -C 6烷氧基),C 3 -C 7环烷基,C 3 -C 7环烯基,芳基, 芳氧基,芳氧基(C 1 -C 4烷氧基),杂环基,杂环氧基,-NR 6 R 7,-NR 8 COR 9,-NR 8 SO 2 R 9,-CONR 6 R -SH,-S(O)pR 1 O,-COR 1或-CO 2 R 1; 其中R 6和R 7各自独立地为H,C 1 -C 4烷基,C 3 -C 7环烷基(任选被羟基或C 1 -C 4烷氧基取代),芳基,芳基(C 1 -C 4烷基),C 2 -C 6烷氧基烷基 ,或杂环基; 或两个基团R 6和R 7与它们所连接的氮一起形成吡咯烷基,哌啶子基,吗啉代,哌嗪基或N-(C 1 -C 4烷基) - 哌嗪基; R 8是H或C 1 -C 4烷基; R 9是C 1 -C 4烷基,CF 3,芳基,芳基(C 1 -C 4烷基),芳基(C 1 -C 4烷氧基),杂环基,C 1 -C 4烷氧基或NR 6 R 7其中R 6, 和R 7如前所定义; R 1是C 1 -C 4烷基,芳基,杂环基或NR 6 R 7,其中R 6和R 7如前所定义; R 1是C 1 -C 4烷基,C 3 -C 7环烷基,芳基或杂环基; R 1是H或C 1 -C 4烷基; p为0,1或2; 或其药学上可接受的盐或其生物前体是具有用于治疗高血压,心力衰竭,肾功能不全和其它病症的利尿剂。

    Verfahren zur Herstellung von Hydroxynaphthalin-sulfonsäureamiden
    48.
    发明公开
    Verfahren zur Herstellung von Hydroxynaphthalin-sulfonsäureamiden 失效
    Verfahren zur Herstellung von Hydroxynaphthalin-sulfonsäureamiden。

    公开(公告)号:EP0263356A2

    公开(公告)日:1988-04-13

    申请号:EP87113874.9

    申请日:1987-09-23

    申请人: BAYER AG

    IPC分类号: C07C311/15

    CPC分类号: C07C303/40 C07C311/29

    摘要: Hydroxynaphthalin-sulfonsäureamide der Formel
    worin
    R, R₁, R₂ = H oder Substituent
    erhält man in einfacher Weise in reiner Form durch Umsetzung von Disulfonamiden der Formel
    mit Alkalien in wäßrigem Medium bei etwa 180 bis 250°C.

    摘要翻译: 通过将式“IMAGE”的二磺酰胺与碱在水介质中的反应在约180至250℃下以简单的方式通过简单的方式获得其中R,R 1和R 2 = H或取代基的式“IMAGE”的羟基萘磺酰胺。 C。

    Process for producing optically active benzene-sulfonamide derivates
    49.
    发明公开
    Process for producing optically active benzene-sulfonamide derivates 失效
    苯磺酰胺衍生物,维他命Zur Herstellung von optisch aktiven Benzensulfonamid-Derivaten。

    公开(公告)号:EP0257787A1

    公开(公告)日:1988-03-02

    申请号:EP87306453.9

    申请日:1987-07-21

    IPC分类号: C07C311/15

    摘要: A process for producing optically active benzenesulfonamide derivative (I)
    which comprises decomposing m-(2-substituted-alkylaminoalkyl)benzene­sulfonamide derivative (II)
    wherein R¹ and R² are selected independently from a hydrogen atom and C₁-C₅ alkyl groups; R³ is a hydrogen atom or a C₁-C₅ alkyl, hydroxyl or C₁-C₅ alkoxyl group; R⁴ is a C₁-C₅ alkyl group; R⁵ is a C₁-C₅ alkyl, carboxy-(C₁-C₅ alkyl) or (C₁-C₅ alkoxy)carbonyl-(C₁-C₅ alkyl) group; and R⁶ is a substituted or unsubstituted phenyl, carboxyl or (C₁-C₅ alkoxy)carbonyl group.
    The compound of formula (II) are obtained by reacting a ketone of formula (III)

    摘要翻译: 制备光学活性苯磺酰胺衍生物(I)的方法其包括分解m-(2-取代 - 烷基氨基烷基)苯磺酰胺衍生物(II)其中R 1和R 2独立地选自氢 原子和C1-C5烷基; R 3是氢原子或C 1 -C 5烷基,羟基或C 1 -C 5烷氧基; R 4是C 1 -C 5烷基; R 5是C 1 -C 5烷基,羧基 - (C 1 -C 5烷基)或(C 1 -C 5烷氧基)羰基 - (C 1 -C 5烷基) R 6是取代或未取代的苯基,羧基或(C 1 -C 5烷氧基)羰基。 式(II)化合物通过使式(III)的酮 x反应而获得

    Diphenyl-methane derivative, pharmaceutical composition and use
    50.
    发明公开
    Diphenyl-methane derivative, pharmaceutical composition and use 失效
    二苯甲烷衍生物,药物Zusammensetzung und Verwendung。

    公开(公告)号:EP0238973A2

    公开(公告)日:1987-09-30

    申请号:EP87103834.5

    申请日:1987-03-17

    申请人: Eisai Co., Ltd.

    摘要: A new diphenyl-methane derivative is useful to inhibit agglomeration of blood and is defined by the formula, including a diphenylethylene derivative and a benzophenone oxime ether derivative.
    in which R1 and R2 each are hydrogen, hydroxyl or a lower alkoxy, U is =CXY or =N-O-W,
    X is hydrogen, cyano or -COR6, R6 being hydroxyl or an amino, Y is -R10-COOR3, R3 being hydrogen or a lower alkoxy, R10 being an alkylene having 1 to 3 carbon atoms, straight or branched, -CO-NR4R5, R4 and R5 each being hydrogen, a lower alkyl or a lower arylalkyl, -CH2-NHSO2-C6H5 or -C(R8)=NR7, R7 being a lower alkoxy or an aryl, R8 is -VR9, V being oxygen, sulfur or nitrogen, R9 being an alkyl or an aryl,
    W is -CH2-CO-CH2-C00R13, R13 being hydrogen or a lower alkyl, -CH2-C(=NOR14)-CH2-COOR15, R15 being hydrogen or a lower alkyl, R14 being a lower alkyl, -CH(CN)-(CH2)q-COOR16, R16 being hydrogen or a lower alkyl, q being an integer of 1 to 3, or -(CH2)p-Z, Z being -SH, -SCN or a monovalent group derived from a five- or six-membered ring which may be substituted by a ring having one or more sulfur atoms in the ring, p being 1 or 2.
    A pharmaceutical composition containing compounds of formula (XX) or their pharmaceutically acceptable salts as active ingredients, and the use of compounds of for­mula (XX) or their pharmaceutically acceptable salts in the preparation of a medicament for treatment of diseases caused by blood stream disorders are also disclosed.

    摘要翻译: 新的二苯基甲烷衍生物可用于抑制血液凝聚,并由式定义,包括二苯基乙烯衍生物和二苯甲酮肟醚衍生物。 其中R 1和R 2各自为氢,羟基或低级烷氧基,U为= XY =或NOW,X为氢,氰基或-COR 6,R6为羟基或氨基,Y为-R10-COOR3,R3 是氢或低级烷氧基,R10是具有1至3个碳原子的直链或支链的亚烷基,-CO-NR4R5,R4和R5各自为氢,低级烷基或低级芳基烷基,-CH2-NHSO2-C6H5或 - C(R8)= NR7,R7为低级烷氧基或芳基,R8为-VR9,V为氧,硫或氮,R9为烷基或芳基,W为-CH2-CO-CH2-C00R13,R13为 氢或低级烷基,-CH 2 -C(= NOR 14)-CH 2 -COOR 15,R 15为氢或低级烷基,R 14为低级烷基,-CH(CN) - (CH 2)q -COOR 16,R 16为氢或 低级烷基,q为1至3的整数,或 - (CH 2)pZ,Z为-SH,-SCN或衍生自五元或六元环的一价基团,其可被具有一个 或更多的硫原子,p为1或2.含有式( XX)或其药学上可接受的盐作为活性成分,并且还公开了式(XX)化合物或其药学上可接受的盐在制备用于治疗由血液病症引起的疾病的药物中的用途。